

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**北 斗 嘉 藥 業 股 份 有 限 公 司**  
**BAYTACARE PHARMACEUTICAL CO., LTD.\***  
*(a joint stock limited company incorporated in the People's Republic of China)*  
**(Stock Code: 8197)**

**DELAY IN PUBLICATION OF ANNUAL RESULTS  
FOR THE YEAR ENDED 31 DECEMBER 2018**

This announcement is made by Baytacare Pharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the GEM Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**GEM Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 8 March 2019.

The Board of Directors of the Company wishes to announce that the Company will be unable to publish the annual results of the Company for the year ended 31 December 2018 (the “**Annual Results**”) on 29 March 2019 as the auditor of the Company requires more time to perform and complete their audit procedures in respect of the Annual Results. Pursuant to Rule 18.49 of the GEM Listing Rules, the Company is required to publish the Annual Results on a date not later than three months after the end of the financial year, i.e. 31 March 2019, therefore the delay in the publication of the announcement of the Annual Results by the Company will constitute non-compliance with Rule 18.49 of the GEM Listing Rules.

Pursuant to Rule 18.48A of the GEM Listing Rules, the Company is required to publish and despatch the annual report for the year ended 31 December 2018 (the “**2018 Annual Report**”) to its shareholders (the “**Shareholders**”) on a date not later than three months after the end of the financial year, i.e. 31 March 2019. As a result of the above mentioned delay in the publication of the Annual Results, the Company will be unable to despatch the 2018 Annual Report to the Shareholders on or before 31 March 2019 pursuant to the GEM Listing Rules. The Company acknowledges that the delay in the publication of the Annual Results and the 2018 Annual Report within three months after the end of the financial year ended 31 December 2018 will constitute non-compliance with Rules 18.49 and 18.48A of the GEM Listing Rules.

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 27 September 2018 and will remain suspended until further notice.

By Order of the Board  
**Baytacare Pharmaceutical Co., Ltd**  
*Executive Director*  
**Cui Bingyan**

Beijing, People's Republic of China, 29 March 2019

*As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Hui Lai Yam, Gao Zhikai and Chen Youfang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Company Announcements" page of the website of GEM at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of the publication and the Company's website at [www.baytacare.com](http://www.baytacare.com) from the date of this announcement.*

\* for identification purposes only